multiple myeloma
Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma
Amneal Pharmaceuticals Inc. and Shilpa Medicare Limited announced the U.S. launch of Boruzu, a new presentation of ...
APRIL 4, 2025
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody Darzalex substantially delayed or prevented transformation of ...
FEBRUARY 20, 2025
Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma
Multiple myeloma, a blood cancer that develops in plasma cells, can result in low blood counts and weakening of the ...
DECEMBER 15, 2024
FDA Approves Sarclisa With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
The FDA has approved Sarclisa with bortezomib, lenalidomide and dexamethasone for adults with newly diagnosed ...
SEPTEMBER 23, 2024
FDA Approves Darzalex Faspro With Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The FDA has approved Darzalex Faspro in combination with bortezomib, lenalidomide and dexamethasone for induction ...
JULY 31, 2024
FDA Approves New Indication for Abecma in Multiple Myeloma
The FDA approved Abecma for adult patients with relapsed or refractory multiple myeloma after two or more prior ...
APRIL 10, 2024
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia and Xgeva.
MARCH 7, 2024
FDA Withdrawals Approval of Pepaxto for Multiple Myeloma
The FDA has announced its final decision to withdraw approval of melphalan flufenamide, which was approved for use ...
FEBRUARY 26, 2024
FDA Approves Darzalex Faspro With Pom-Dex for Multiple Myeloma
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) in combination with pomalidomide and ...
JULY 15, 2021
FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma
The FDA approved Abecma to treat adults with relapsed or refractory multiple myeloma who have received at least ...
MARCH 31, 2021
FDA Approves Pepaxto for Triple-Refractory Multiple Myeloma
The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with ...
MARCH 5, 2021
New Monoclonal Antibody Approved to Treat Relapsed/Refractory MM
The FDA approved isatuximab-irfc (Sarclisa, Sanofi) in combination with pomalidomide (Pomalyst, Celgene) and ...
MARCH 3, 2020
